Abstract
Mutations of the von Hippel-Lindau gene (VHL) are frequent in clear cell renal cell carcinomas (ccRCC). Nonsense and frameshift mutations abrogate the function of the VHL protein (pVHL), whereas missense mutations can have different effects. To identify those missense mutations with functional consequences, we sequenced VHL in 256 sporadic ccRCC and identified 187 different VHL mutations of which 65 had missense mutations. Location and destabilizing effects of VHL missense mutations were determined in silico. The majority of thermodynamically destabilizing missense mutations were located in exon 1 in the core of pVHL, while protein surface mutations in exon 3 affected the interaction domains of elongin B and C. Their impact on pVHL's functionality was further investigated in vitro by stably re-introducing VHL missense mutations into a VHL null cell line and by monitoring the GFP signals after the transfection of a HIFα-GFP expression vector. pVHL's functionality ranged from no effect to complete HIF stabilization. Interestingly, Asn78Ser, Asp121Tyr, and Val130Phe selectively influenced HIF1α and HIF2α degradation. In sum, we obtained three different groups of missense mutations: one with severe destabilization of pVHL, a second without destabilizing effects on pVHL but relevance for the interaction with HIFα, elongin B, or elongin C, and a third with pVHL functions comparable to wild-type. We therefore conclude that the specific impact of missense mutations may help to distinguish between driver and passenger mutations and may explain responses of ccRCC patients to HIF targeted therapies.pVHL's functionality ranged from no effect to complete HIF stabilization. Interestingly, Asn78Ser, Asp121Tyr, and Val130Phe selectively influenced HIF1α and HIF2α degradation. In sum, we obtained three different groups of missense mutations: one with severe destabilization of pVHL, a second without destabilizing effects on pVHL but relevance for the interaction with HIFα, elongin B, and elongin C, and a third with pVHL functions comparable to wild-type. We therefore conclude that the specific impact of missense mutations may help to distinguish between driver and passenger mutations and may explain responses of ccRCC patients to HIF targeted therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.